Novel treatment strategies for malignant melanoma : A new beginning?KASPER, Bernd; D'HONDT, Veronique; VEREECKEN, Pierre et al.Critical reviews in oncology/hematology. 2007, Vol 62, Num 1, pp 16-22, issn 1040-8428, 7 p.Article

Novel treatment strategies for soft tissue sarcomaKASPER, Bernd; GIL, Thierry; D'HONDT, Veronique et al.Critical reviews in oncology/hematology. 2007, Vol 62, Num 1, pp 9-15, issn 1040-8428, 7 p.Article

Hautveränderungen durch targeted therapies bei onkologischen Patienten : Kutane Nebenwirkungen zielgerichteter Therapie bei onkologischen Patienten = Skin changes as a result of targeted therapies in oncology patients ·Cutaneous side effects of targeted therapies in oncology patientsKÄHLER, K. C; HAUSCHILD, A.Der Hautarzt. 2009, Vol 60, Num 5, pp 433-439, issn 0017-8470, 7 p.Article

Mast cells and cancer-No longer just basic scienceGALINSKY, Daliah Shoshana Tamar; NECHUSHTAN, Hovav.Critical reviews in oncology/hematology. 2008, Vol 68, Num 2, pp 115-130, issn 1040-8428, 16 p.Article

From Targets to Treatments: A Review of Molecular Targets in Pancreatic Neuroendocrine TumorsWIEDENMANN, Bertram; PAVEL, Marianne; KOS-KUDLA, Beata et al.Neuroendocrinology (Basel). 2011, Vol 94, Num 3, pp 177-190, issn 0028-3835, 14 p.Article

Blockade of epidermal growth factor receptor (EGFR) activityJIMENO, Antonio; HIDALGO, Manuel.Critical reviews in oncology/hematology. 2005, Vol 53, Num 3, pp 179-192, issn 1040-8428, 14 p.Article

Biology and management of relapsed acute myeloid leukaemiaCRADDOCK, Charles; TAURO, Sudhir; MOSS, Paul et al.British journal of haematology. 2005, Vol 129, Num 1, pp 18-34, issn 0007-1048, 17 p.Article

Novel therapies for myelodysplastic syndromesFADERL, Stefan; KANTARJIAN, Hagop M.Cancer. 2004, Vol 101, Num 2, pp 226-241, issn 0008-543X, 16 p.Article

Current treatments and promising investigations in a multidisciplinary settingVOKES, E.Annals of oncology. 2005, Vol 16, pp vi25-vi30, issn 0923-7534, SUP6Conference Paper

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directionsGUALBERTO, A; POLLAK, M.Oncogene (Basingstoke). 2009, Vol 28, Num 34, pp 3009-3021, issn 0950-9232, 13 p.Article

Current therapeutic strategies for acute myeloid leukaemiaKOLITZ, Jonathan E.British journal of haematology. 2006, Vol 134, Num 6, pp 555-572, issn 0007-1048, 18 p.Article

Monoclonal antibodies in the treatment of multiple myelomaRICHARDSON, Paul G; LONIAL, Sagar; JAKUBOWIAK, Andrzej J et al.British journal of haematology. 2011, Vol 154, Num 6, pp 745-754, issn 0007-1048, 10 p.Article

Maximum tolerated dose: clinical endpoint for a bygone era?TAKIMOTO, Chris H.Targeted oncology. 2009, Vol 4, Num 2, pp 143-147, issn 1776-2596, 5 p.Article

The insulin-like growth factor-I receptor as an oncogeneWERNER, Haim; BRUCHIM, Ilan.Archives of physiology and biochemistry. 2009, Vol 115, Num 2, pp 58-71, issn 1381-3455, 14 p.Conference Paper

Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancerCRUZ, J. J; OCANA, A; DEL BARCO, E et al.Annals of oncology. 2007, Vol 18, Num 3, pp 421-430, issn 0923-7534, 10 p.Article

A review of tumour lysis syndrome with targeted therapies and the role of rasburicaseBOSE, P; QUBAIAH, O.Journal of clinical pharmacy and therapeutics (Print). 2011, Vol 36, Num 3, pp 299-326, issn 0269-4727, 28 p.Article

Investigator-initiated trials of targeted oncology agents: why independent research is at risk?BERGMANN, L; BERNS, B; ZWIERZINA, H et al.Annals of oncology. 2010, Vol 21, Num 8, pp 1573-1578, issn 0923-7534, 6 p.Article

Current Adjuvant and Targeted Therapies for Pancreatic AdenocarcinomaSANCHEZ, Sabrina E; TREVINO, Jose G.Current medicinal chemistry. 2008, Vol 15, Num 17, pp 1674-1683, issn 0929-8673, 10 p.Article

Molecular targets in melanoma : Strategies and challenges for diagnosis and therapyHERLYN, Meenhard.International journal of cancer. 2006, Vol 118, Num 3, pp 523-526, issn 0020-7136, 4 p.Article

Epigenetics and OncologyMUMMANENI, Padmaja; SHORD, Stacy S.Pharmacotherapy. 2014, Vol 34, Num 5, pp 495-505, issn 0277-0008, 11 p.Article

Immunseneszenz: Bestandsaufnahme und molekulare Grundlagen : Hautalterung/Anti-Aging-Strategien = Immunosenescence. Current status and molecular mechanisms : Skin Aging/Anti-aging StrategiesPETERS, T.Der Hautarzt. 2011, Vol 62, Num 8, pp 598-606, issn 0017-8470, 9 p.Article

Toxicity of targeted therapy: Implications for response and impact of genetic polymorphismsLIU, Sariah; KURZROCK, Razelle.Cancer treatment reviews. 2014, Vol 40, Num 7, pp 883-891, issn 0305-7372, 9 p.Article

Alpha-particles for targeted therapySGOUROS, George.Advanced drug delivery reviews. 2008, Vol 60, Num 12, pp 1402-1406, issn 0169-409X, 5 p.Article

Kutane Nebenwirkungen der medikamentösen Tumortherapie : Medikamentöse Tumortherapie in der dermatologie = Cutaneous side effects of medical tumor therapy : Medical tumor therapy in dermatologyDEGEN, A; ALTER, M; SCHENCK, F et al.Der Hautarzt. 2011, Vol 62, Num 6, pp 444-450, issn 0017-8470, 7 p.Article

Targeted therapy-induced radiation recallLEVY, Antonin; HOLLEBECQUE, Antoine; DEUTSCH, Eric et al.European journal of cancer (1990). 2013, Vol 49, Num 7, pp 1662-1668, issn 0959-8049, 7 p.Article